Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

A legfontosabb adatok

Ki végzi
Vaxcyte, Inc.
Hol
Birmingham, Charlottesville, Chinle, Cincinnati, Gallup, Gulfport, Hollywood, Jupiter, Kansas City, Lenexa, Miami, New Orleans, Norman, North Charleston, Omaha, Philadelphia, Ridgeland, Riverside, Rochester, Salt Lake City, San Antonio, Shiprock, Southfield, Stockbridge, Sugar Land, Sunrise, Toms River, Valparaiso, Whiteriver és Wichita (Egyesült Államok)Mind a 30 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
4049 fő vett részt
Kezdés
2025. dec. 1.
Befejezés
2026. szept. 17.
A vizsgálat típusa
Beavatkozással járó, 5 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • 31 valent pneumococcal conjugate vaccine
  • PCV20
  • PCV21
A regiszteradat frissítve
2026. október 16.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 24 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female ≥18 years of age (inclusive) at the time of randomization into the study
  • Able and willing to complete the informed consent process
  • Available for clinical follow-up through the last study visit
  • In good general health or with stable underlying chronic condition(s), as determined by medical history, oral temperature, physical examination, and clinical judgment of the Investigator (ongoing chronic conditions must be documented as stable per Investigator)
  • Willing to have blood samples collected and used for research purposes
  • Able to provide proof of identity to the satisfaction of the site personnel completing the enrollment process
  • Female participants of childbearing potential, defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test immediately prior to randomization and agree to use acceptable contraception. Male subjects with partners of childbearing potential must agree to practice an acceptable contraception method
  • Able to access and use a device connected to Wi-Fi or cellular network for completion of an electronic diary (eDiary)

Ki nem vehet részt

  • Previous receipt of any licensed or investigational pneumococcal vaccine at any age
  • Receipt of any investigational product within 30 days prior to Day 1, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study
  • Receipt of any live vaccine within 30 days prior to Day 1, or receipt of any non-live (including inactivated) vaccine within 14 days prior to Day 1
  • Body temperature >38.0°C (>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescreened)
  • History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination
  • Receipt of blood or blood product (including polyclonal intravenous immunoglobulin) within 60 days prior to enrollment into the study
  • Is currently receiving immunosuppressive or immune-modifying therapy, including systemic corticosteroids (this includes ≥3 months of prednisone equivalent from 5 to <10 mg/day and ≥2 weeks of prednisone equivalent ≥10 mg/day)
  • Received any part of a ≥14-day course of systemic corticosteroids (prednisone equivalent >10 mg/day) within 14 days of study vaccination
  • Current diagnosis of human immunodeficiency virus, Hepatitis B, or Hepatitis C
  • Has a known or suspected immunocompromising condition, including, but not limited to, leukemia, lymphoma, chronic renal failure, or congenital or acquired immunodeficiency
  • Any medical, psychiatric, or social condition that in the judgment of the Investigator is a contraindication to protocol participation or impairs a subject's ability to give informed consent
  • Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) resulting in clinically significant bruising or bleeding difficulties with IM injections or blood draws
  • History of invasive pneumococcal disease (IPD) or pneumococcal pneumonia (either confirmed or self-reported) at any age
  • History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
  • Individual who is pregnant, breastfeeding, or planning to become pregnant during study participation
  • Employee of, or first-degree relative of, any person employed by the Sponsor, the contract research organization (CRO), the Investigator, site personnel, or site

Helyszínek itt: Egyesült Államok

  • Accel Research Site - Achieve - Birmingham - ERNBirmingham, Egyesült Államok
  • Charlottesville Medical Research Center - Alcanza - HyperCoreCharlottesville, Egyesült Államok
  • Center for Indigenous Health - Chinle - Johns Hopkins ProjectChinle, Egyesült Államok
  • CTI Clinical Research CenterCincinnati, Egyesült Államok
  • Center for Indigineous Health - Gallup - John Hopkins ProjectGallup, Egyesült Államok
  • DelRicht Research, LLC - GulfportGulfport, Egyesült Államok
  • Research Centers of America - Hollywood - CenExelHollywood, Egyesült Államok
  • Health Awareness - Jupiter - ERNJupiter, Egyesült Államok
  • Alliance for Multispecialty Research, LLC - Kansas CityKansas City, Egyesült Államok
  • Johnson County Clin-Trials (JCCT)Lenexa, Egyesült Államok
  • Suncoast Research Group, LLCMiami, Egyesült Államok
  • DelRicht Clinical Research, LLC - New OrleansNew Orleans, Egyesült Államok
  • Lynn Institute of NormanNorman, Egyesült Államok
  • Coastal Carolina Research Center - Alcanza - HyperCoreNorth Charleston, Egyesült Államok
  • Velocity Clinical ResearchOmaha, Egyesült Államok
  • DM Clinical Research - PhiladelphiaPhiladelphia, Egyesült Államok
  • SKY Integrative Medical Center/SKYCRNGRidgeland, Egyesült Államok
  • Clinical Innovations Trials - Riverside - CenExelRiverside, Egyesült Államok
  • Rochester Clinical Research - ATLAS - RochesterRochester, Egyesült Államok
  • JBR Clinical Research - CenExel JBRSalt Lake City, Egyesült Államok
  • Flourish Research San AntonioSan Antonio, Egyesült Államok
  • Center for Indigineous Health - Shiprock - John Hopkins ProjectShiprock, Egyesült Államok
  • Headlands Research - Detroit - HeadlandsSouthfield, Egyesült Államok
  • Clinical Research Atlanta - HeadlandsStockbridge, Egyesült Államok
  • DM Clinical Research - SugarlandSugar Land, Egyesült Államok
  • Precision Clinical Research - SunriseSunrise, Egyesült Államok
  • Advanced Memory Research Institute - CenExeToms River, Egyesült Államok
  • Velocity Clinical Research - Valparaiso (Buynak Clinical Research)Valparaiso, Egyesült Államok
  • Center for Indigineous Health - Whiteriver - John Hopkins ProjectWhiteriver, Egyesült Államok
  • Alliance for Multispecialty Research, LLC - West WichitaWichita, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objectives of this study are to evaluate the safety, tolerability, immunologic noninferiority (for shared serotypes) and immunologic superiority (for novel serotypes) of VAX-31 compared to PCV21 and PCV20 in adults ≥50 years of age, and to bridge the immune responses induced by VAX-31 in adults 50-64 years of age to adults 18-49 years of age.

A vizsgálat 5 csoportja

  • Cohort 1 (VAX-31), participant ≥ 50 years of ageA vizsgált kezelés

    Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1

    Kezelés: 31 valent pneumococcal conjugate vaccine

  • Cohort 1 (PCV21), participant ≥ 50 years of ageMár használt kezelés, összehasonlításként

    Participants will receive a single dose of PCV21 (Capvaxive) administered via intramuscular injection at Day 1

    Kezelés: PCV21

  • Cohort 1 (PCV20), participant ≥ 50 years of ageMár használt kezelés, összehasonlításként

    Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1

    Kezelés: PCV20

  • Cohort 2 (VAX-31), participant 18-49 years of ageA vizsgált kezelés

    Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1

    Kezelés: 31 valent pneumococcal conjugate vaccine

  • Cohort 2 (PCV20), participant 18-49 years of ageMár használt kezelés, összehasonlításként

    Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1

    Kezelés: PCV20

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Immunobridging to Subjects 18-49 Years of Age
A regiszteradat frissítve
2026. október 16.